
Caspian Oliai, MD, MS
Advertisement
Articles by Caspian Oliai, MD, MS


Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and myelodysplastic syndrome (MDS).
Advertisement
Latest Updated Articles
- Orca-T Shows Efficacy, Reduced GVHD Risk in Acute Leukemia, MDS
Published: May 1st 2025 | Updated:
- Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS
Published: April 11th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5